Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Pass Above 200-Day Moving Average - What's Next?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.53 and traded as high as $4.76. Vanda Pharmaceuticals shares last traded at $4.68, with a volume of 335,590 shares traded.

Wall Street Analyst Weigh In

VNDA has been the topic of a number of recent research reports. Wall Street Zen raised Vanda Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th.

Vanda Pharmaceuticals Stock Performance

The company has a 50-day moving average price of $4.45 and a 200-day moving average price of $4.53. The firm has a market capitalization of $294.30 million, a price-to-earnings ratio of -6.66 and a beta of 0.68.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.05. The business had revenue of $50.04 million during the quarter, compared to analysts' expectations of $45.13 million. Vanda Pharmaceuticals had a negative return on equity of 8.30% and a negative net margin of 21.98%. On average, research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Insider Activity

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 7,000 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $4.59, for a total transaction of $32,130.00. Following the transaction, the director owned 97,082 shares of the company's stock, valued at approximately $445,606.38. This trade represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Mihael Hristos Polymeropoulos acquired 20,000 shares of the company's stock in a transaction on Friday, May 16th. The shares were purchased at an average cost of $4.22 per share, for a total transaction of $84,400.00. Following the acquisition, the chief executive officer owned 2,315,731 shares of the company's stock, valued at approximately $9,772,384.82. The trade was a 0.87% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 10.00% of the company's stock.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently made changes to their positions in VNDA. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Vanda Pharmaceuticals by 4.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock worth $3,925,000 after purchasing an additional 38,449 shares during the last quarter. Monaco Asset Management SAM grew its holdings in shares of Vanda Pharmaceuticals by 92.8% during the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock worth $1,879,000 after purchasing an additional 188,836 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Vanda Pharmaceuticals by 2.1% during the fourth quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company's stock worth $1,438,000 after purchasing an additional 6,079 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth about $649,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Vanda Pharmaceuticals by 108.9% during the fourth quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company's stock worth $1,608,000 after purchasing an additional 175,019 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.